PROBE Patient Relevant Osteoarthritis endpoints using Big data Evaluation
- Coordinator
- Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
- Runs
- 1 December 2025 to 30 November 2030
- Status
- Running
- EU funding
- €14.0m
- Total cost
- €26.4m
- Partners
- 46 organisations in 16 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101219324
What the project is doing
In the project's own words, from its summary on CORDIS.
Osteoarthritis (OA) causes pain, disability, and economic burden for 500+ million people. Developing disease modifying osteoarthritis drugs is crucial, but challenging due to disease heterogeneity, slow progression, and regulatory issues. The PROBE consortium addresses these challenges by integrating diverse and disparate datasets, combined with all necessary expertise, creating a federated database network. PROBE will unite critical mass in OA data and multidisciplinary disease specific expertise, federated infrastructure experts, AI and ML expertise, data privacy and ethics experts, health economics and outcome researchers, and indispensable patient, HTA, and regulatory perspectives experts, to achieve significant advancements in trial designs and tools for shared decision making.
The overarching aim of PROBE is to deliver data-driven opportunities for the treatment of OA, through enhancements in patient stratification, predicative modelling, patient/caregiver interface decision tools and clinical trial design. Outcomes include a federated and regulatory compliant database network of disparate OA data for powerful, innovative big data methodology. In close collaboration with key stakeholders, we will also provide novel multimodal and relevant endpoints to test emerging treatments, models to enable stratified medicine and support shared prognostic and treatment decision-making and Health Technology Assessment.
The impact of PROBE encompasses the foundation for advanced clinical trial design, predictive models for OA progression, novel endpoints, stratified patient subgroups and the ability to target treatments to patients’ needs and preferences, and tools that enable specific functional measurements and reflect real-life treatment benefits. The PROBE consortium holds the potential to reshape the landscape of OA clinical trials/treatment and ultimately improve the lives of all people affected by OA.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Coordinator |
| Research Institute AG & Co Kg | Wien | Austria | Participant |
| Sba Research Gemeinnutzige GmbH | Wien | Austria | Participant |
| Ablynx NV | Zwijnaarde | Belgium | Associatedpartner |
| Moveup | Bruxelles | Belgium | Participant |
| Universite De Liege | Liege | Belgium | Participant |
| Universiteit Hasselt | Hasselt | Belgium | Participant |
| Sanofi Medley Farmacêutica Ltda | São Paulo | Brazil | Associatedpartner |
| Novartis Pharma AG | Basel | Switzerland | Participant |
| Apheris Ai GmbH | Berlin | Germany | Participant |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Chondrometrics GmbH - Medical Data Processing | Freilassing | Germany | Participant |
| Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH | Neuherberg | Germany | Participant |
| Sanofi-Aventis Deutschland GmbH | Frankfurt Am Main | Germany | Associatedpartner |
| Siemens Healthineers AG | Forchheim | Germany | Participant |
| Universitatsklinikum Erlangen | Erlangen | Germany | Participant |
| University of Hamburg | Hamburg | Germany | Participant |
| Nordic Bioscience A/s | Herlev | Denmark | Participant |
| Nordic Bioscience Clinical Development A/s | Herlev | Denmark | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Region Hovedstaden | Hillerod | Denmark | Participant |
| Syddansk Universitet | Odense M | Denmark | Participant |
| Tartu Ulikool | Tartu | Estonia | Participant |
| Servizo Galego De Saude | Santiago De Compostela | Spain | Participant |
| Synapse Research Management Partners SL | Madrid | Spain | Participant |
| Oulun Yliopisto | Oulu | Finland | Participant |
| Assistance Publique Hopitaux De Paris | Paris | France | Participant |
| Capgemini Consulting | Issy-Les-Moulineaux | France | Participant |
| Sanofi Winthrop Industrie | Gentilly | France | Participant |
| Sanofi-Aventis Recherche & Developpement | Gentilly | France | Associatedpartner |
| University College Dublin, National University of Ireland, Dublin | Dublin | Ireland | Participant |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| Sanofi B.V. | Amsterdam | Netherlands | Associatedpartner |
| Stichting ReumaNederland | Amsterdam | Netherlands | Participant |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| Direktoratet for Medisinske Produkter | Oslo | Norway | Participant |
| Lunds Universitet | Lund | Sweden | Participant |
| Glaxosmithkline Research & Development Limited | London | United Kingdom | Participant |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Participant |
| The University of Nottingham | Nottingham | United Kingdom | Participant |
| University of Leeds | Leeds | United Kingdom | Participant |
| University of Southampton | Southampton | United Kingdom | Participant |
| Pacira Pharmaceuticals, Inc. | Wilmington | United States | Participant |
| Rhino Federated Computing, Inc. | Boston | United States | Participant |
| Sanofi Genzyme | Cambridge | United States | Associatedpartner |
| Sanofi US Services Inc. | Cambridge, Massachusetts | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI